sotalol has been researched along with Arrhythmogenic Right Ventricular Dysplasia in 12 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Arrhythmogenic Right Ventricular Dysplasia: A congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RIGHT VENTRICLE wall and loss of myocardial cells. Primary injuries usually are at the free wall of right ventricular and right atria resulting in ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 5.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 1.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "We present a case of ventricular tachycardia with clinical features suggestive of arrhythmogenic right ventricular cardiomyopathy." | 1.38 | Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy. ( Chia, PL; Kuchar, D; Subbiah, RN; Walker, B, 2012) |
| "Arrhythmogenic right ventricular cardiomyopathy is a desmosomal disease." | 1.37 | Guidelines for the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy. ( Smith, W, 2011) |
| "Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2." | 1.35 | Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. ( Cannom, DS; Estes, NA; Glidden, DV; Marcus, F; Marcus, GM; Polonsky, B; Scheinman, MM; Smith, LM; Zareba, W, 2009) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| "Arrhythmogenic right ventricular dysplasia is a rarely diagnosed cardiomyopathy, but a frequent cause of ventricular arrhythmia and sudden cardiac death." | 1.30 | QT dispersion in patients with arrhythmogenic right ventricular dysplasia. ( Benn, M; Hansen, PS; Pedersen, AK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 1 |
| Ermakov, S | 2 |
| Hoffmayer, KS | 1 |
| Gerstenfeld, EP | 2 |
| Scheinman, MM | 3 |
| Svetlichnaya, Y | 1 |
| Marcus, GM | 1 |
| Glidden, DV | 1 |
| Polonsky, B | 1 |
| Zareba, W | 1 |
| Smith, LM | 1 |
| Cannom, DS | 1 |
| Estes, NA | 1 |
| Marcus, F | 1 |
| Mitchell, LB | 1 |
| Smith, W | 1 |
| Chia, PL | 1 |
| Subbiah, RN | 1 |
| Kuchar, D | 1 |
| Walker, B | 1 |
| Hariman, RJ | 1 |
| Khin, MM | 1 |
| Zoble, RG | 1 |
| Amlie, JP | 1 |
| Benn, M | 1 |
| Hansen, PS | 1 |
| Pedersen, AK | 1 |
| Wolk, R | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Randomized Trial With Flecainide in ARVC Patients[NCT03685149] | Phase 2 | 23 participants (Actual) | Interventional | 2019-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for sotalol and Arrhythmogenic Right Ventricular Dysplasia
| Article | Year |
|---|---|
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr | 2014 |
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Catheter Ablation; Combin | 2017 |
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2009 |
Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism?
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dy | 2009 |
Guidelines for the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Defibrillators, Impl | 2011 |
Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy.
Topics: Adrenal Cortex Hormones; Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; | 2012 |
Wide QRS Tachycardia in a young patient.
Topics: Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Blood Pressure; Defibrillators, | 2012 |
Increased dispersion of repolarization in patients with arrhythmogenic right ventricular dysplasia--a major electrophysiological factor responsible for malignant ventricular arrhythmias.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Electrocardio | 1999 |
QT dispersion in patients with arrhythmogenic right ventricular dysplasia.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Electrocardio | 1999 |
Is QT dispersion a reliable index of heterogeneity of ventricular repolarization and a pro-arrhythmic marker?
Topics: Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Electrocardiography; Heart Condu | 2000 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |